Key result
Nonischemic LGE linked to ~498% greater risk of HF events in patients with prior MI.
Why the study?
Does the presence of nonischemic late gadolinium enhancement on CMR predict heart failure or sudden cardiac death events in patients with prior myocardial infarction?
Cohort (n=948)
Does the presence of nonischemic late gadolinium enhancement on CMR predict heart failure or sudden cardiac death events in patients with prior myocardial infarction?
Nonischemic late gadolinium enhancement on CMR in patients with prior myocardial infarction is a strong independent predictor of subsequent heart failure events, providing incremental prognostic value beyond LVEF and infarct size.
Answers are grounded in this paper and cite their sources.
May enhance post-MI HF risk stratification on CMR; leaves open prospective validation before guiding care.
Background The prevalence, anatomic distribution, enhancement patterns, and prognostic value of nonischemic late gadolinium enhancement (NI‐LGE) in patients with prior myocardial infarction were not systematically investigated. Methods A total of 948 patients (mean±SD age, 56.2±10.9 years; 88.4% men) diagnosed with prior myocardial infarction by cardiac magnetic resonance imaging were analyzed, excluding those with coexisting nonischemic cardiomyopathies or myocarditis. NI‐LGE was defined as midwall or subepicardial enhancement. Competing risk analysis was performed to mitigate the influence of competing events. Results Among these, NI‐LGE was observed in 78 patients (8.2%), with septal involvement present in all cases. Lower left ventricular ejection fraction (odds ratio [OR]=0.97, P =0.01) and larger end‐diastolic volume index (OR=1.01, P <0.001) were independently associated with NI‐LGE. During a median follow‐up of 69.6 months (interquartile range, 49.7–80.9 months), 99 (10.4%) and 63 (6.6%) experienced heart failure (HF)– and sudden cardiac death–related events, respectively. NI‐LGE was associated with a markedly increased risk of HF‐related events (subdistribution hazard ratio [sHR]=5.98, P <0.001) after adjusting for the confounders, but not sudden cardiac death ( P =0.65). NI‐LGE improved the model discrimination and fit performance (C‐index: 0.84–0.87; likelihood ratio: 1168.0–1106.1, both P <0.001) for the HF‐related events beyond left ventricular ejection fraction and late gadolinium enhancement extent. Moreover, NI‐LGE involving both the septum and free wall conferred a higher risk of HF‐related events than isolated septal involvement (sHR=2.42, P =0.02). Conclusions NI‐LGE occurs in 8.2% of patients with prior myocardial infarction, predominantly involving the interventricular septum. As a potential marker of adverse remodeling, NI‐LGE might provide incremental prognostic value for HF‐related outcomes beyond traditional markers.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) conducted a cohort in prior myocardial infarction (n=948). Nonischemic late gadolinium enhancement (NI-LGE) vs. Absence of NI-LGE was evaluated on heart failure (HF)-related events (sHR 5.98, p=<0.001). Nonischemic late gadolinium enhancement was associated with a markedly increased risk of heart failure-related events in patients with prior myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: